Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1966 1
1971 3
1972 4
1974 3
1975 2
1976 1
1977 1
1978 1
1981 3
1982 1
1983 1
1984 6
1985 3
1986 1
1987 3
1988 5
1989 3
1990 4
1991 4
1992 2
1993 2
1994 5
1995 1
1996 4
1997 4
1998 3
1999 2
2000 4
2001 7
2002 9
2003 2
2004 9
2005 6
2006 11
2007 10
2008 10
2009 9
2010 13
2011 16
2012 14
2013 16
2014 16
2015 16
2016 26
2017 16
2018 17
2019 23
2020 13
2021 24
2022 25
2023 26
2024 16

Text availability

Article attribute

Article type

Publication date

Search Results

392 results

Results by year

Filters applied: . Clear all
Page 1
Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE).
Haratani K, Nakamura A, Mamesaya N, Mitsuoka S, Yoneshima Y, Saito R, Tanizaki J, Fujisaka Y, Hata A, Tsuruno K, Sakamoto T, Teraoka S, Oki M, Watanabe H, Sato Y, Nakano Y, Otani T, Sakai K, Tomida S, Chiba Y, Ito A, Nishio K, Yamamoto N, Nakagawa K, Hayashi H. Haratani K, et al. Among authors: oki m. J Thorac Oncol. 2023 Oct;18(10):1334-1350. doi: 10.1016/j.jtho.2023.06.012. Epub 2023 Jun 25. J Thorac Oncol. 2023. PMID: 37364849
Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.
Sakamoto T, Matsubara T, Takahama T, Yokoyama T, Nakamura A, Tokito T, Okamoto T, Akamatsu H, Oki M, Sato Y, Tobino K, Ikeda S, Mori M, Mimura C, Maeno K, Miura S, Harada T, Nishimura K, Hiraoka M, Kenmotsu H, Fujimoto J, Shimokawa M, Yamamoto N, Nakagawa K. Sakamoto T, et al. Among authors: oki m. JAMA Netw Open. 2023 Dec 1;6(12):e2347700. doi: 10.1001/jamanetworkopen.2023.47700. JAMA Netw Open. 2023. PMID: 38100106 Free PMC article.
Response.
Oki M, Saka H. Oki M, et al. Chest. 2016 Oct;150(4):985-986. doi: 10.1016/j.chest.2015.10.025. Chest. 2016. PMID: 27719821 No abstract available.
Response.
Oki M, Saka H. Oki M, et al. Chest. 2015 Oct;148(4):e130. doi: 10.1378/chest.15-1457. Chest. 2015. PMID: 26437825 No abstract available.
A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy.
Takeda M, Shimokawa M, Nakamura A, Nosaki K, Watanabe Y, Kato T, Hayakawa D, Tanaka H, Takahashi T, Oki M, Tachihara M, Fujimoto D, Hayashi H, Yamaguchi K, Yamamoto S, Iwama E, Azuma K, Hasegawa K, Yamamoto N, Nakagawa K. Takeda M, et al. Among authors: oki m. Lung Cancer. 2023 Mar;177:44-50. doi: 10.1016/j.lungcan.2023.01.011. Epub 2023 Jan 28. Lung Cancer. 2023. PMID: 36731290 Free article. Clinical Trial.
Time-study research on maxillofacial prosthetic treatment.
Murase M, Fujita H, Oki M, Yoshioka F, Nishiyama Y, Ohyama T, Matsumoto C, Usui S, Sato Y, Sado T, Takahashi H, Sasaki K, Matsuyama M, Sumita Y. Murase M, et al. Among authors: oki m. Jpn Dent Sci Rev. 2024 Dec;60:73-80. doi: 10.1016/j.jdsr.2023.12.007. Epub 2024 Jan 17. Jpn Dent Sci Rev. 2024. PMID: 38298267 Free PMC article. Review.
392 results